557 related articles for article (PubMed ID: 15917550)
1. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
2. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
4. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
7. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
Ip M; Chau SS; Chi F; Qi A; Lai RW
J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
9. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
10. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
11. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
12. gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.
Kivata MW; Mbuchi M; Eyase FL; Bulimo WD; Kyanya CK; Oundo V; Muriithi SW; Andagalu B; Mbinda WM; Soge OO; McClelland RS; Sang W; Mancuso JD
BMC Microbiol; 2019 Apr; 19(1):76. PubMed ID: 30961546
[TBL] [Abstract][Full Text] [Related]
13. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
[TBL] [Abstract][Full Text] [Related]
16. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
17. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
Patel SN; Melano R; McGeer A; Green K; Low DE
Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
[TBL] [Abstract][Full Text] [Related]
20. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
